2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831
(Norristown, Pennsylvania, USA, 31 October 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it received approval from ANSM, the French Health Authority, to sell its unique and advanced PluroGel® PSSD and PluroGel® Burn and Wound in France.
The Advanced Wound Care Market in France is estimated by the Company to be a $680 million opportunity for PluroGen. While France is part of the European Union participating in the pan-European CE Mark System of medical device approval, France has its own internal system, managed by its national health authority, ANSM, to allow life science products to be sold. ANSM approval to sell is a big step forward for PluroGen, opening the opportunity to enter the French market.
“PluroGen has achieved another important milestone. Our PluroGel® Products are already achieving superior patient results in the USA and a number of countries in Europe compared to the competition. With ANSM approval, we can now begin our search for corporate partners and distributors in France.” commented Neal Koller, President and CEO of PluroGen. “Having France’s ANSM approval adds another valuable asset to the Company, opens another large market opportunity and enhances shareholder value”.
For Immediate Release
31 October 2013
Contact: Tricia Thompson
+1 (610) 539-3670